Inclusion Criteria:

• Healthy participants between ≥ 50 and ≤ 80 years of age without a dysproteinemia diagnosis.

Exclusion Criteria:  

• Clinically significant abnormality due to the presence of an M-spike assessed via SPEP, elevated FLC or abnormal FLC ratio, elevated IgG, IgA, or IgM levels
• Clinically diagnosed hematologic abnormalities: clonal hematopoesis of indeterminate significance (CHIP), clonal cytopenias of undetermined significance (CCUS), idiopathic cytopenias of unclear significance (ICUS), bone marrow failure syndromes, immune deficiencies or autoimmune conditions (e.g., lupus), myeloproliferative disorder, or hematologic malignancy
• Clinically significant (within the past 5 years) liver disease, active malignancy (e.g., breast cancer), malabsorption syndrome, severe chronic obstructive pulmonary disease, untreated gallbladder disease, history of MI or stroke, or history of thrombophlebitis or deep venous thrombosis
• Undergoing treatment with any of the following drugs: adrenocorticoid steroids (3 months or longer at anytime or > 10 days of treatment within the previous 12 months), anticonvulsant therapy (within the previous year), bisphosphonates, denosumab, teriparatide, abaloparatide, or romosozumab within the past 3 years, any prior treatment with systemic chemotherapy
• Clinical history of any osteoporotic fracture within the previous three years
• Ongoing or active infection
• Current pregnancy.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 3/13/23. Questions regarding updates should be directed to the study team contact.